TIDMUPR
RNS Number : 7480U
Uniphar PLC
08 April 2021
Publication of Notice of Annual General Meeting and Annual
Report
Dublin, London | 8 April 2021: Uniphar plc (the "Company" or
"Uniphar") wishes to announce that it is today posting to
shareholders its Notice of Annual General Meeting ("AGM") for 2021
together with its annual report and accounts for the year ended 31
December 2020 ("Annual Report"). The AGM will be held at 11.00 a.m.
on 12 May 2021 at Uniphar's registered office, 4045 Kingswood Road,
Citywest Business Park, Dublin 24, D24 V06K.
Uniphar considers the well-being of shareholders, employees and
attendees a top priority. Based on the latest available guidance
from the Health Service Executive ("HSE") in Ireland, the board of
directors of Uniphar (the "Board") expect the AGM to proceed on 12
May 2021 but under very constrained circumstances. Given the
severity of the circumstances and the health risks involved,
Uniphar's directors will take all appropriate safety measures to
ensure the safety of attendees and others involved in the AGM,
including restricting attendance at the AGM, should it be deemed
necessary or desirable.
The Notice of meeting, Form of Proxy, Annual Report and accounts
are available to view on the Company's website at
https://www.uniphar.ie/static/investors /shareholder-centre/AGM and
will be available for inspection during normal business hours on
any business day from today until the conclusion of the AGM at the
registered office of the Company. In accordance with applicable
regulations and public health guidelines in force in Ireland in
connection with Covid-19, shareholders are requested not to
physically attend the Company's registered office to inspect those
documents and are instead requested to inspect those documents
online.
Public Health Guidelines and the AGM
The Company is closely monitoring and adhering to public health
measures prescribed by the Government of Ireland and the Department
of Health relating to Covid-19. The Company has a legal obligation
to hold this AGM, and while it is expected that the AGM will
proceed as planned on 12 May 2021, it is likely to do so under very
constrained circumstances. To avoid unnecessary risk to the
Company's shareholders, employees and other attendees, the Company
recommends shareholders to participate in the AGM by electronic
means, including by casting their proxy votes electronically in
advance of the meeting. Details of how to do so are set out in
further detail in the Circular.
A listen only conference call facility will be provided to allow
shareholders to listen to the business of the meeting. Please note
that this facility will allow you to listen to the business of the
AGM only, you will not be able to use this facility to vote, raise
points or issues, ask questions or table resolutions. If you wish
to listen live to the AGM proceedings, you can register for the
conference call and receive participant log-in details at
https://www.uniphar.ie/static/investors/shareholder-centre/AGM
.
Shareholders availing of this facility should also ensure to
submit their Form of Proxy by the relevant deadline in advance of
the AGM, as it will not be possible to vote using the conference
call facility.
Shareholders are invited to submit questions in writing in
advance of the meeting either by email to
companysecretary@uniphar.ie or by post to the Company Secretary,
Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co.
Dublin, D24 V06K, Ireland. Questions must be received by 11.00 a.m.
on 10 May 2021 . Shareholders must include their Shareholder
Reference Number (as set out on their Form of Proxy) with any
question submitted.
The Company continues to monitor the impact of Covid-19 and any
relevant updates regarding the AGM, including any changes to the
arrangements outlined in this Notice, will be announced via stock
exchange announcement and will be available on
https://www.uniphar.ie/static/investors/shareholder-centre/AGM
.
In the event that it is not possible to hold the AGM either in
compliance with public health guidelines or applicable law or where
it is otherwise considered that proceeding with the AGM as planned
poses an unacceptable health and safety risk, the AGM may be
adjourned or postponed or relocated to a different time and/or
venue, in which case notification of such adjournment or
postponement or relocation will be given in accordance with
applicable law.
For further details contact:
Uniphar +353 (0) 1 428 7777
Brian O'Shaughnessy
------------------------------
Group Director of Corporate Development investor.relations@Uniphar.ie
------------------------------
Davy +353 (0) 1 679 6363
------------------------------
(Joint Corporate Broker, Nominated Adviser
and Euronext
Growth Adviser)
------------------------------
Fergal Meegan
------------------------------
Barry Murphy
------------------------------
Niall Gilchrist
------------------------------
RBC Capital Markets (Joint Corporate Broker) +44 (0) 20 7653 4000
------------------------------
Jonathan Hardy
------------------------------
Jamil Miah
------------------------------
Stifel Nicolaus Europe Limited (Joint Corporate
Broker) +44 (0) 20 7710 7600
------------------------------
Matt Blawat
------------------------------
Ben Maddison
------------------------------
Francis North
------------------------------
Q4 PR +353 (0) 1 475 1444
or
------------------------------
(Public Relations Adviser to Uniphar) +353 87 235 6461
------------------------------
Iarla Mongey
------------------------------
About Uniphar plc
Headquartered in Dublin, Ireland, Uniphar plc ("Uniphar" and
together with its subsidiaries the "Group") is an international
diversified healthcare services business, servicing the
requirements of more than 200 multinational pharmaceutical and
medical technology manufacturers across three divisions -
Commercial & Clinical, Product Access and Supply Chain &
Retail.
With a workforce in excess of 2,600, the Group is active in
Ireland, the UK, Benelux, the Nordics, and the US, delivering
unlicensed and specialty medicine on a global basis.
The Group's vision is to improve patient access to
pharmaco-medical products and treatments by enhancing connectivity
between manufacturers and healthcare stakeholders. Uniphar
represents a strong combination of scale, growth, and
profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing
& distribution solutions to multinational pharmaceutical and
medical device manufacturers on an outsourced basis. Active in
Ireland, the UK, Benelux, the Nordics and the US, the Group is
growing with its clients to provide pan-European solutions. Uniphar
has built a fully integrated multi-channel solution that is
supported by our highly experienced and clinically trained teams
leveraging our digital technology and insights which allows us to
deliver consistently exceptional outcomes for our clients.
Product Access
In Product Access the Group is growing two distinct service
offerings: 1) "On Demand Access", which are pharmacy led solutions
for sourcing and supplying unlicensed medicines to meet the needs
of both retail and hospital pharmacists; and 2) "Exclusive Access",
which are manufacturer led solutions for controlling the release of
speciality medicines for specifically approved patient populations
in agreed markets. The Group currently delivers product access
solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with over a
50% market share in the wholesale/hospital market, supported by a
network of c.330 owned, franchised and symbol group pharmacies. The
business supports the diverse customer base through the provision
of strong service levels coupled with innovative commercial
initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and
infrastructure are utilised for the benefit of the growth
divisions, Commercial & Clinical and Product Access.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAIRMPTMTMMBMB
(END) Dow Jones Newswires
April 08, 2021 02:00 ET (06:00 GMT)
Uniphar (LSE:UPR)
Historical Stock Chart
From Apr 2024 to May 2024
Uniphar (LSE:UPR)
Historical Stock Chart
From May 2023 to May 2024